Proposed regulations for the Prescription Monitoring Program were published in the NJ Register on 11/16/15.
(View Proposed Regulations)
For too many New Jerseyans, addiction begins in the medicine cabinet.
Please be advised that beginning March 1, 2015, pharmacies will be required to report information to the NJPMP on a daily basis using the ASAP 4.2 format. . Prescriptions must be reported to the database no more than one (1) business day after the date the controlled substance was dispensed. In order to help facilitate any software conversion that may be necessary, the NJPMP will defer enforcement until September 1, 2015.
The New Jersey Prescription Monitoring Program (NJPMP) is an important component of the New Jersey Division of Consumer Affairs' initiative to halt the abuse and diversion of prescription drugs.
Established pursuant to N.J.S.A. 45:1-45 et. seq., the NJPMP is a statewide database that collects prescription data on Controlled Dangerous Substances (CDS) and Human Growth Hormone (HGH) dispensed in outpatient settings in New Jersey, and by out-of-state pharmacies dispensing into New Jersey. Pharmacies are required to submit this data weekly.
The Division of Consumer Affairs and the NJPMP Administrator keep patient information strictly confidential, in compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules.
Access by Prescribers and Pharmacists
Access to the NJPMP is granted to prescribers and pharmacists who are licensed by the State of New Jersey and in good standing with their respective licensing boards.
Before issuing a prescription or dispensing a prescribed drug, qualified prescribers and pharmacists who have registered to use the NJPMP are able to access the NJPMP website and request the CDS and HGH prescription history of the patient. The users must certify that they are seeking information for a specific, current patient.
Patient information in the NJPMP is intended to supplement an evaluation of a patient, confirm a patient's drug history, or document compliance with a therapeutic regimen. When prescribers or pharmacists identify a patient as potentially having an issue of concern regarding drug use, they are encouraged to help the patient locate assistance and take any other action the prescriber or pharmacist deems appropriate.
The New Jersey Division of Consumer Affairs and its private contractor keep NJPMP patient information strictly confidential, in compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules.
Prescribers and pharmacists authorized to access the NJPMP, must certify before each search that they are seeking data solely for the purpose of providing healthcare to current patients. Authorized users agree that they will not provide access to the NJPMP to any other individuals, including members of their staff.
A prescriber or pharmacist who accesses or discloses NJPMP information for any purpose other than providing healthcare to a current patient or verifying the NJPMP's record of prescriptions issued by the prescriber, or who allows any other individuals to access the NJPMP using the prescriber's or pharmacist's own access codes, is subject to civil penalties of up to $10,000 for each offense and disciplinary action by the prescriber's or pharmacist's professional licensing board.
Any individual who suspects that another individual or entity has accessed or disclosed patient information in violation of the NJPMP Statute or Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules, should immediately contact the NJPMP Administrator at email@example.com or call the Division of Consumer Affairs at 800-242-5846.
Help Us Fight Prescription Drug Abuse
The New Jersey Division of Consumer Affairs invites all members of the public to help in the fight to halt the abuse and diversion of prescription drugs.
The statistics on prescription drug abuse are staggering.
In 2010, New Jersey saw 7,238 admissions to State-licensed or certified substance abuse treatment programs as a result of prescription painkiller abuse. That number represents a dramatic increase of nearly 2,000 from the previous year's admissions, and an increase of more than 5,000 from 2005, according to statewide statistics.
In June 2011, the New Jersey State Commission of Investigation reported that a growing number of young people are abusing prescription drugs, and noted a significant trend in which the practice has led to increases, not only in the number of young people addicted to painkillers, but to the number of young people using heroin as well.
Every day, 40 Americans die from an overdose caused by prescription painkiller abuse, according to the U.S. Centers for Disease Control and Prevention. Overdoses of opioid prescription drugs now kill more people in the U.S. than heroin and cocaine combined.
Consumers can learn the best ways to dispose of unused medications, and to keep medications safe within their homes, at our Project Medicine Drop website.
Individuals seeking additional information about prescription drug abuse – including ways to talk with their family members about the dangers of drug abuse, and information for those struggling with addiction – can find it at our Useful Links page.